News

Vireo Growth Inc. Announces Effective Date of New Ticker Symbols

– Subordinate voting shares to begin trading under new ticker symbols today, July 8, 2024 – – Ticker symbol “VREO”…

1 year ago

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,…

1 year ago

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today…

1 year ago

Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK…

1 year ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish…

1 year ago

Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

Single infusion of FLT201 at low dose of 4.5e11 vg/kg demonstrates compelling safety and benefit Expect to initiate Phase 3…

1 year ago

BrightSpring Health Services Earns Multiple Accreditations Across the Country for Quality Care

LOUISVILLE, Ky., July 08, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading…

1 year ago

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development…

1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct…

1 year ago

Kraig Biocraft Laboratories Announces New Spider Silk Production Contract

ANN ARBOR, Mich., July 08, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"),…

1 year ago